• Real-World Tirzepatide Therapy in Post-Bariatric Weight Regain and Preoperative Obesity Patients

  NCT07382180

  CompletedObservationalUpdated Feb 3, 2026
• Effect of Tirzepatide on Cardiovascular and Metabolic Parameters in Obese Adult Patients With Congenital Heart Disease

  NCT07354880

  Not yet recruitingInterventionalPhase 4Updated Jan 21, 2026
• A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)

  NCT07247084

  RecruitingInterventionalPhase 4Updated Jul 7, 2026
• Tirzepatide Use in People With Obesity and Type 1 Diabetes

  NCT07096908

  RecruitingInterventionalPhase 4Updated Apr 20, 2026
• Tirzepatide Titration to Reduce Side Effects in Individuals With Obesity

  NCT07574723

  RecruitingInterventionalNot ApplicableUpdated Jul 8, 2026
• A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight

  NCT04184622

  CompletedInterventionalPhase 3Updated Jul 24, 2025

ClinicalTrials.gov ID

NCT07504172

Lead Sponsor

Radboud University Medical CenterOTHER

Overall Status

Not yet recruiting

Study Type

Observational

Enrollment

1,700Estimated

Last Update Posted

Mar 31, 2026Actual

Start Date

Apr 1, 2026Estimated

Primary Completion Date

Jul 1, 2026Estimated

Completion Date

Aug 1, 2026Estimated

Official Title

Real-world Effectiveness and Dosing Patterns of Tirzepatide: A Multicentre Retrospective Observational Study in the Netherlands

Brief Summary

Tirzepatide is one of the new medications for the treatment of obesity. In clinical research people treated with Tirzepatide have weight loss up to 21%. But there is only a little bit of research showing the effect of Tirzepatide in clinical practice.

In this retrospective observational study the investigators will evaluate the effectiveness of tirzepatide in routine clinical practice among adults with obesity in the Netherlands.The main questions it aims to answer are:

• How much weight do patients lose after six months of treatment with tirzepatide combined with lifestyle coaching?
• How is the medication dosed in daily practice? Researchers will use data from electronic health records of patients in multiple outpatient locations of the Dutch Obesity Clinic (NOK, Nederlandse Obesitas Kliniek).

• Overweight , Obesity
• Obesity (Disorder)

• Tirzepatide

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Adults (age ≥18 years old)
• A BMI of ≥ 30 kg/m2 or a BMI ≥ 27 kg/m2 with at least one obesity complication (e.g., hypertension, dyslipidaemia)

Exclusion Criteria:

• Pregnant women or pregnancy during treatment
• Previously treated for obesity (with pharmacotherapy, endoscopic treatment or metabolic-bariatric surgery)
• Patients with diabetes

Observational Model

Cohort

Time Perspective

Retrospective

Lead Sponsor

Radboud University Medical CenterOTHER

Collaborators

Nederlandse Obesitas KliniekOTHER

pvandenhooff@obesitaskliniek.nl+31649653657